Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Cohort Evaluating the Determinants of Radiation-Induced Skin Complications in Patients With Head and Neck Cancer Receiving Preventive Photobiomodulation

NCT07899866 is registered in ClinicalTrials.gov with Hopital Forcilles as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07899866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Cohort Evaluating the Determinants of Radiation-Induced Skin Complications in Patients With Head and Neck Cancer Receiving Preventive Photobiomodulation
Lead sponsor
Hopital Forcilles
Phase
Observational
Overall status
Not yet recruiting
Start date
November 2, 2026
Completion date
November 30, 2028
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 1 arm.

  • Head and neck cancer patients receiving radiotherapy with preventive PBM External beam radiotherapy, Functional, quality-of-life and photographic assessments, Preventive photobiomodulation

    Adults with head and neck cancer treated with curative-intent external beam radiotherapy (exclusive or adjuvant, with or without concomitant chemotherapy) exposing the cervical skin, who receive preventive photobiomodulation as part of standard care.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Number of Participants With Grade 2 or Higher Radiation Dermatitis Assessed by NCI-CTCAE v5.0 From the first to the last radiotherapy session, approximately 7 weeks

    Occurrence of radiation dermatitis of grade 2 or higher according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 (moderate to brisk erythema, moist desquamation mostly confined to skin folds and/or moderate edema, or worse), assessed at each PBM session (3 times per week). Clinical, demographic, tumor-related, treatment-related and PBM-related factors associated with this outcome will be identified by univariate analyses and multivariable logistic regression.

Lead sponsor's other trials

Hopital Forcilles, most recent start first.

Similar trials

Same condition (Radiodermatitis) and phase, most recent start first.